TotalMarketCap

Crescent Biopharma

CBIONasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$482.128 M

$12.98 -6.08%

Close of 6 Nov 2026

As of 6 Nov 2026, Crescent Biopharma (CBIO) has a market capitalization of $482.1M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$10.8M

#3122 by revenue

Earnings

$153.9K

#2421 by earnings

Shares outstanding

37,143,940

Latest filing cover page

P/E ratio

3131.9

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #190DiaMedica TherapeuticsDMAC$488.6M
  2. #191Indaptus TherapeuticsINDP$483.8M
  3. #192Crescent BiopharmaCBIO$482.1M
  4. #193CytomX TherapeuticsCTMX$467.4M
  5. #194Aquestive TherapeuticsAQST$458.1M

What if Crescent Biopharma were worth as much as…

Open the what-if tool →

Gold $28.2T

$760,201.36

Per share 58,567× higher

Bitcoin $1.53T

$41,133.17

Per share 3,169× higher

Apple $5.02T

$135,036.36

Per share 10,403× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Crescent Biopharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.